Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMR3VCY)

• Drug Name: MP0250 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Non-small-cell lung cancer	2C25.Y	Phase 1/2	[1]

• Cross-matching ID: TTD Drug ID: DMR3VCY

Molecule-Related Drug Atlas

Drug(s) Targeting Vascular endothelial growth factor A (VEGFA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aflibercept	DMT3D5I	Central retinal vein occlusion with macular edema		Approved	[2]
Brolucizumab	DMW8QNG	Wet age-related macular degeneration	9B78.3Z	Approved	[3]
Faricimab	DM83SEB	Diabetic macular edema	9B71.02	Approved	[4]
Ranibizumab	DMSYPNW	Central retinal vein occlusion with macular edema		Approved	[5]
Bevacizumab	DMSD1UN	Adenocarcinoma	2D40	Approved	[6]
Avastin+/-Tarceva	DMA86FL	Non-small-cell lung cancer	2C25.Y	Phase 3	[7]
PTC299	DMP9TKE	Rheumatoid arthritis	FA20	Phase 2	[8]
RG7221	DM8J9DC	Colorectal cancer	2B91.Z	Phase 2	[9]
RO5520985	DMD3WNP	Colorectal cancer	2B91.Z	Phase 2	[10]
Abicipar pegol	DM59OJ2	Diabetic macular edema	9B71.02	Phase 2	[11]

Drug(s) Targeting Hepatocyte growth factor (HGF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
VM-202	DMSW80U	Angina pectoris	BA40	Phase 3	[12]
Donaperminogene seltoplasmid	DMH8IT5	Diabetic foot ulcer	BD54	Phase 3	[13]
ANG-3777	DMGP8WX	Delayed graft function	4B24.0	Phase 3	[14]
Ficlatuzumab	DMG65WH	Multiple myeloma	2A83	Phase 2	[1]
Collategene	DM27H0P	Peripheral Ischemic Ulcers	BD41	Phase 2	[15]
ABI-011	DM1KD7U	Lymphoma	2A80-2A86	Phase 1	[1]
TAK-701	DML3M0O	Advanced malignancy	2A00-2F9Z	Phase 1	[16]
Rilotumumab	DMD8ZSW	Grade IV malignant glioma	2A00.0	Discontinued in Phase 2	[17]
N,O6-Disulfo-Glucosamine	DMYCV7U	Discovery agent	N.A.	Investigative	[18]
O2-Sulfo-Glucuronic Acid	DME78MS	Discovery agent	N.A.	Investigative	[18]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Hepatocyte growth factor (HGF)	TT4V2JM	HGF_HUMAN	Inhibitor	[1]
Vascular endothelial growth factor A (VEGFA)	TTOHSBA	VEGFA_HUMAN	Inhibitor	[1]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [4] Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases. Expert Opin Investig Drugs. 2021 Mar;30(3):193-200.
• [5] Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006 Oct;26(8):859-70.
• [6] FDA Approved Drug Products from FDA Official Website. 2004. Application Number: (ANDA) 125085.
• [7] Clinical pipeline report, company report or official report of Genentech (2009).
• [8] Phase I and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study.J Neurooncol.2015 Jan;121(1):217-24.
• [9] Bispecific antibodies and their applications
• [10] Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.
• [11] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [12] Therapeutic angiogenesis using naked DNA expressing two isoforms of the hepatocyte growth factor in a porcine acute myocardial infarction model. Eur J Cardiothorac Surg. 2008 Oct;34(4):857-63.
• [13] Clinical pipeline report, company report or official report of ViroMed.
• [14] Hepatocyte Growth Factor Mimetic ANG-3777 for Cardiac Surgery-Associated Acute Kidney Injury. Kidney Int Rep. 2020 Sep 25;5(12):2325-2332.
• [15] Randomized, double-blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia. Gene Ther. 2010 Sep;17(9):1152-61.
• [16] Targeting MET in cancer: rationale and progress.Nat Rev Cancer.2012 Jan 24;12(2):89-103.
• [17] Clinical pipeline report, company report or official report of Amgen (2009).
• [18] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.